Despite these positive attributes, we have modest expectations for Invokana and the SGLT-2 class because the drug and class are associated with a relatively high rate of genital infections which will limit uptake in our view.

FORBES: Analyst: Higher Rate Of Genital Fungal Infections Could Curb Sales Of New J&J Drug